Vernon-Roberts Angharad, Otley Anthony, Frampton Chris, Gearry Richard B, Day Andrew S
University of Otago (Christchurch), Department of Pediatrics, Christchurch, New Zealand.
Dalhousie University Department of Pediatrics, Halifax, Nova Scotia, Canada.
Inflamm Intest Dis. 2020 Jun;5(2):70-77. doi: 10.1159/000506200. Epub 2020 Feb 21.
For children with inflammatory bowel disease (IBD), acquired knowledge of their condition and treatment is integral to their adherence and self-management. Assessing their knowledge is vital to identify deficits that may affect disease management. IBD-KID2 is a knowledge assessment tool written for children aged 8 years and over with IBD.
In order to examine validity and reliability, a study was carried out using IBD-KID2 in a paediatric IBD population and a number of comparator groups with established levels of IBD knowledge.
IBD-KID2 was administered to 4 participant groups in Christchurch Hospital, New Zealand: children with IBD ( = 22), children without IBD ( = 20), medical staff ( = 15), and administration staff ( = 15). Between-group differences were tested using ANOVA and pairwise comparisons made with the IBD group. Repeat assessments by the IBD group determined test-retest reliability ( = 21).
The mean age (range) of the paediatric groups were: IBD 13.3 years (8-18), without IBD 11.9 years (8-15). Group mean scores (SD) were: IBD 8.5 (±2.3), without IBD 3.7 (±2.2), medical staff 13.5 (±1.3), administration staff 6.3 (±2.5). Group means were all significantly different to the IBD group. Test-retest mean at baseline (8.4, CI ±2.4) and repeat (9.0, CI ±2.4) were not significant. Intraclass correlation coefficient was 0.82. Internal reliability was 0.85, and item-total statistics showed no improvement by specific item removal.
IBD-KID2 could distinguish between groups with different knowledge levels. Repeat assessment shows comparable scores on retest and good reproducibility. IBD-KID2 is a valid and reliable tool for use in the paediatric IBD population.
对于炎症性肠病(IBD)患儿而言,了解自身病情及治疗方法对于他们坚持治疗和自我管理至关重要。评估他们的知识水平对于识别可能影响疾病管理的不足之处至关重要。IBD-KID2是一种为8岁及以上IBD患儿编写的知识评估工具。
为了检验有效性和可靠性,在儿科IBD人群以及一些具有既定IBD知识水平的对照群体中使用IBD-KID2进行了一项研究。
在新西兰克赖斯特彻奇医院,IBD-KID2被施用于4个参与组:IBD患儿(n = 22)、非IBD患儿(n = 20)、医务人员(n = 15)和行政人员(n = 15)。使用方差分析检验组间差异,并与IBD组进行两两比较。IBD组的重复评估确定了重测信度(n = 21)。
儿科组的平均年龄(范围)为:IBD组13.3岁(8 - 18岁),非IBD组11.9岁(8 - 15岁)。组平均得分(标准差)为:IBD组8.5(±2.3),非IBD组3.7(±2.2),医务人员13.5(±1.3),行政人员6.3(±2.5)。所有组的平均值与IBD组均有显著差异。基线时的重测平均值(8.4,置信区间±2.4)和重复测量时(9.0,置信区间±2.4)无显著差异。组内相关系数为0.82。内部信度为0.85,项目总分统计显示去除特定项目后无改善。
IBD-KID2能够区分不同知识水平的组。重复评估显示重测分数具有可比性且再现性良好。IBD-KID2是用于儿科IBD人群的有效且可靠的工具。